Home > Resources > Whitepapers > Pharma R&D Annual Review 2017

Pharma R&D Annual Review 2017

February 3, 2017

Welcome to Pharmaprojects’ 2017 review of trends in pharmaceutical R&D. For around a quarter of a century now, I’ve been taking an annual look at the evolution of pharma R&D, and in this article, I’ll look at how the land lies at the start of 2017. We’ll assess industry trends by examining the pipeline by company, therapeutic area, disease, target and drug type, using data from Pharma Intelligence’s Phamaprojects, which has been tracking global drug development since 1980. This report will be followed up by our annual supplement reviewing the New Active Substance launches for the year just past. But here, we will be focusing on research and development as it is now, how it is changing and mutating, and where it has been headed during 2016.

Spotlight

Emitac Healthcare Solutions

With more than 40 years of experience in the industry, our integrated team of professionals have deployed several Clinical and IT Solutions in a number of leading government, semi government, Military and private hospitals in the MENA region. With our extensive market knowledge and well established partnerships with some of the world’s leading healthcare and technology providers, we continue delivering the highest standards of quality care. Through our unique combination of workforce empowerment, process improvement and technology optimization, we offer reliable and cost effective solutions to our customers to achieve sustainable results.

OTHER WHITEPAPERS

The Age of Coaching

whitePaper | March 4, 2022

The pandemic has been healthcare and the pharmaceutical industry’s meteor moment established eco-systems have been wiped out andsales force routines have been scorched from the face of the earth.

Asia Pacific – Clinical trial landscape

whitePaper | November 8, 2022

The Asia-Pacific region has emerged as a clinical trial hub due to the ease of regulatory compliance, low trial costs, rising patient population, and the availability of top clinical institutions.

2022 Global Life Sciences Outlook

whitePaper | January 3, 2022

While valuations for the life sciences sector in this past year have been mixed, the underlying performance and outlook for the

Deck 7 Webinars and Virtual Events

whitePaper | January 1, 2020

If you recognize some of these challenges, download the Deck 7 Webinar & Virtual Events overview to see how we make it easy for busy marketers to run highly successful webinars and virtual events....

Manufacturing High-Quality Capsule Products for Pharmaceutical and Nutraceutical Applications

whitePaper | October 25, 2022

To confirm the suitability of empty hard capsules for use in the application of quality-by-design (QbD) in the development and manufacturing of finished pharmaceutical products, the quality target product profile (QTPP) defined by eight critical quality attributes (CQA’s) was examined.

More Whitepapers

Pharma R&D Annual Review 2017